[Optimization of PNS/TGCO components effect on experimental Qi stagnation and blood stasis type of coronary heart disease with increase-decrease baseline geometric proportion design method].
OBJECTIVE
Preliminary exploration of Panax notoginseng saponins (PNS) and total saponins from Cornus officinalis (TGCO) components treatment and characteristics of Qi stagnation and blood stasis type of coronary heart disease.


METHODS
With increase-decrease baseline geometric proportion design method to Optimization of PNS/TGCO components, through observing different proportions effective components effect on mice with pituitrin-induced acute myocardial ischemia and the time of hypoxia tolerance.


RESULTS
Prescriptions 1, 2, 3 and Xuesaitong groups had a certain degree of improvement the role of myocardial ischemia and prescriptions 4, 5, 6, compared with the control group with no significant changes; Prescriptions 3, 4, 5, 6 had a certain role in anti-anoxia in mice, prescriptions 1, 2 and Xuesaitong group, together with the control group with no significant changes.


CONCLUSIONS
Prescription 3 has some effect on improving the role of myocardial ischemia and has a certain role in anti-anoxia. It's the best ratio of PNS/TGCO components for the treatment of Qi stagnation and blood stasis type of coronary heart disease.
Shanxi University of Chinese Medicine, Xianyang 712046, China. tzs6565@163.com
Zhi-Shu
ZS
Tang
Li-Wei
LW
Guo
Bin
B
Wang
Yan-Ping
YP
Song
D000284:Administration, Oral; D000818:Animals; D002626:Chemistry, Pharmaceutical; D029768:Cornus / Q000737:chemistry; D004195:Disease Models, Animal; D004338:Drug Combinations; D004365:Drugs, Chinese Herbal / Q000737:chemistry / Q000494:pharmacology*; D004562:Electrocardiography; D005260:Female; D036145:Ginsenosides / Q000008:administration & dosage* / Q000494:pharmacology; D000860:Hypoxia / Q000188:drug therapy* / Q000517:prevention & control; D008297:Male; D051379:Mice; D017202:Myocardial Ischemia / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D053723:Panax notoginseng / Q000737:chemistry; D010909:Pituitary Hormones, Posterior / Q000008:administration & dosage; D019413:Qi; D051381:Rats; D017207:Rats, Sprague-Dawley; D012503:Saponins / Q000008:administration & dosage* / Q000494:pharmacology; D014665:Vasodilator Agents / Q000494:pharmacology*
D004338:Drug Combinations; D004365:Drugs, Chinese Herbal; D036145:Ginsenosides; D010909:Pituitary Hormones, Posterior; D012503:Saponins; D014665:Vasodilator Agents